Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1 ‐ JAK2 , BCR‐JAK2 and ETV6‐ABL1 fusion genes-Reference-Cited by-同舟云学术

Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1 ‐ JAK2 , BCR‐JAK2 and ETV6‐ABL1 fusion genes

Published:2020-04-28 Issue:7 Volume:95 Page:824-833
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Schwaab Juliana¹^ORCID,Naumann Nicole¹,Luebke Johannes¹,Jawhar Mohamad¹,Somervaille Tim C.P.²³,Williams Mark S.²³,Frewin Rebecca⁴,Jost Philipp J.⁵,Lichtenegger Felix S.⁶,La Rosée Paul⁷,Storch Nicola⁸,Haferlach Torsten⁹,Horny Hans‐Peter¹⁰,Fabarius Alice¹,Haferlach Claudia⁹,Burchert Andreas¹¹,Hofmann Wolf‐Karsten¹,Cross Nicholas C.P.¹²¹³,Hochhaus Andreas¹⁴,Reiter Andreas¹,Metzgeroth Georgia¹

Affiliation:

1. Department of Hematology and OncologyUniversity Hospital Mannheim, Heidelberg University Mannheim Germany

2. Department of HaematologyThe Christie NHS Foundation Trust Manchester UK

3. Cancer Research UK Manchester Institute Manchester UK

4. Department of PathologyGloucester Royal Hospital Gloucester UK

5. III. Medical Department, Hematology and OncologyKlinikum rechts der Isar, Technical University Munich Munchen Bayern Germany

6. Department of Medicine IIIUniversity Hospital LMU Munich Munich Germany

7. Klinik für Innere Medizin II, Schwarzwald‐Baar‐Klinikum Villingen‐Schwenningen Germany

8. Department of Hematology and OncologySt. Vincenz Medical Centre Limburg Germany

9. Munich Leukemia Laboratory Munich Germany

10. Department of PathologyUniversity of Munich Munich Germany

11. Department of Hematology, Oncology and ImmunologyPhilipps University Marburg, and University Medical Center Giessen and Marburg Marburg Germany

12. Faculty of MedicineUniversity of Southampton Southampton UK

13. Wessex Regional Genetics Laboratory Salisbury UK

14. Klinik für Innere Medizin IIUniversitätsklinikum Jena Jena Germany

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25825

Reference59 articles.

1. Myeloid neoplasms with eosinophilia

2. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma

3. Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase

4. Five years since the discovery of FIP1L1–PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploration of ETV6::ABL1-positive AML with concurrent NPM1 and FLT3-ITD mutations;Annals of Hematology;2024-08-06

2. TLE3 Is a Novel Fusion Partner of JAK2 in Myeloid/Lymphoid Neoplasm With Eosinophilia Responding to JAK2 Inhibition;Genes, Chromosomes and Cancer;2024-08

3. A case report of right‐sided heart failure secondary to JAK2‐mutation Loeffler endocarditis;ESC Heart Failure;2024-07-31

4. ETV6::ABL1 fusion: from overlooked minor clone in myeloproliferative neoplasm to major player in leukemic transformation;Virchows Archiv;2024-07-27

5. Approach to the patient with eosinophilia in the era of tyrosine kinase inhibitors and biologicals;Current Hematologic Malignancy Reports;2024-07-22